08037.HK
China Biotech Services Holdings Limited
HKSE · Healthcare · Medical - Diagnostics & Research · HK
HKD 0.47
−4.08%Year over year
Reported trailing growth
- Revenue
- +88.9%
- EBITDA
- -39.3%
- EBIT
- —
- EPS
- +87.7%
- Free cash flow
- —
- Operating cash flow
- +3.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -65.9%
- EBITDA
- +52.0%
- EBIT
- +46.9%
- Net income
- +65.3%
- EPS
- +64.8%
- Free cash flow
- +3.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026